Clinical Research
corporate_fare

IGI Therapeutics S.A.

Address
Rue Du Puits-Godet 8

Sponsor Overview

assignment
1
sponsored trial
science
0
molecules
location_city
15
research centres
public
4
countries
person_search
12
investigators

Specializations

Hematologic Oncology

IGI Therapeutics S.A. is involved in clinical research focused on relapsed/refractory multiple myeloma, addressing a difficult-to-treat plasma cell malignancy with unmet therapeutic need.

  • Multiple myeloma
  • Relapsed disease
  • Refractory disease

The sponsor’s research activity is centered on advancing treatment options for patients whose disease has returned or no longer responds to prior therapy.

Novel Anticancer Biologics

The company’s clinical portfolio includes investigation of an experimental biologic therapy designed for use in oncology, reflecting interest in new treatment modalities for blood cancers.

  • Investigational biologics
  • Anticancer therapy
  • Targeted treatment approaches

This area highlights development work in therapies intended to address resistant malignancies through innovative biological mechanisms.

Immuno-Oncology

IGI Therapeutics S.A. shows therapeutic interest in immune-based cancer treatment, particularly strategies relevant to the management of hematologic tumors such as multiple myeloma.

  • Immune-mediated therapy
  • Hematologic cancer
  • Tumor-directed immune activity

Its research focus includes approaches that seek to improve control of disease in patients with limited remaining treatment options.

Biologics Development and Process Sciences

As a biologics manufacturing and process sciences entity, the sponsor’s clinical research interests are aligned with the translation of complex biologic platforms into oncology studies.

  • Biologics manufacturing
  • Process sciences
  • Clinical translation

This area connects laboratory development capabilities with the clinical evaluation of advanced therapeutic candidates in cancer care.

Sponsored Trials

Trial Name Country Status
Phase I Study of ISB 2001 in Patients with Relapsed or Refractory Multiple MyelomaFrance FranceItaly ItalyNorway NorwaySpain SpainRecruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
0
Exclusive Molecules
out of 0 total (0% not shared with other sponsors)

This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
0%
Return partnership rate
0 of 15 sites collaborated multiple times

This sponsor has worked with 15 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Hemic and Lymphatic Diseases1 trial
    249 other sponsors

Partnered Research Centres

15 centres
location_city
assignment1015
Centre Hospitalier Universitaire De Lille
Address
Rue Michel Polonovski, 59037 Lille
Learn morearrow_forward
location_city
assignment1093
Centre Hospitalier Universitaire De Nantes
Address
1 Place Alexis Ricordeau, 44000 Nantes
Learn morearrow_forward
location_city
assignment633
Centre Hospitalier Universitaire De Poitiers
Address
2 Rue De La Miletrie, 86000 Poitiers
Learn morearrow_forward
location_city
assignment563
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Address
Via Francesco Sforza 28, 20122 Milan
Learn morearrow_forward
location_city
assignment1617
Hopital Beaujon
Address
100 Boulevard Du General Leclerc, 92110 Clichy
Learn morearrow_forward
location_city
assignment151
Hopital Saint Antoine
Address
184 Rue Du Faubourg Saint Antoine, 75571 Paris
Learn morearrow_forward
Page 1 of 3

Want to get in touch with this sponsor?

Send a question and we'll pass it on to IGI Therapeutics S.A..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.